Global Dry Eye Syndrome Therapeutics Market Report to 2029 - Featuring Abbott, AbbVie, Allergan and AstraZeneca Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Dry Eye Syndrome Therapeutics Market Analysis by Product Type, by Disease Type, and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

The dry eye syndrome (DES) therapeutics market size is estimated to be USD 4,310 million in 2021 and is expected to witness a CAGR of 9.45% during the forecast period 2022-2029.

The growing number of persons who get dry eyes, increasing healthcare costs, and a rise in the volume of R&D activity are some of the primary market drivers.

However, the significant financial burden of therapy, a scarcity of competent personnel, and a lack of healthcare facilities in emerging economies, restrictive drug approval procedures used by testing organizations cause the launch of new medications to be delayed are expected to restrain the market growth.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including product type, and disease type from 2022-2029.

Segmentation:

Dry Eye Syndrome (DES) Therapeutics Market Analysis Report 2021-2029

Product Type (Revenue, USD Million)

• Punctal Plugs
• Cyclosporine
• Artificial Tears
• Omega Supplements
• Oral Corticosteroid

Disease Type (Revenue, USD Million)

• Aqueous Dry Eye Syndrome
• Evaporative Dry Eye Syndrome

By Region (Revenue, USD Million)

North America

• U.S.
• Canada

Europe

• Germany
• France
• UK
• Spain
• Italy
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of APAC

Latin America

• Brazil
• Mexico
• Argentina
• Rest of LATAM

Middle East & Africa

• South Africa
• GCC
• Rest of MEA

Companies Mentioned

• Abbott (US)
• AbbVie Inc. (US)
• Merck & Co. Inc. (US)
• Akorn Operating Company LLC (US)
• Allergan (Ireland)
• Allostera Pharma Inc. (Canada)
• AstraZeneca (UK)
• Eli Lilly and Company (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• GlaxoSmithKline plc (UK)
• I-Med Pharma Inc. (Canada)
• Johnson & Johnson Private Limited (US)
• Merck KGaA (Germany)
• Novaliq GmbH (Germany)
• Novartis AG (Switzerland)
• Otsuka America Pharmaceutical Inc. (US)
• Pfizer Inc. (US)
• Sanofi (France)
• Santen Pharmaceuticals Co. Ltd. (Japan)
• Teva Pharmaceutical Industries Ltd. (Jerusalem)

For more information about this report visit https://www.researchandmarkets.com/r/dmiqt9

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900